Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Top Cited Papers
- 1 October 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (13), 1324-1334
- https://doi.org/10.1016/s1470-2045(15)00188-6
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Emerging landscape of oncogenic signatures across human cancersNature Genetics, 2013
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Attitudes of Patients With Cancer About Personalized Medicine and Somatic Genetic TestingJournal of Oncology Practice, 2012
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agentsBritish Journal of Cancer, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005